| FUNDAMENTALS |
| MarketCap: |
0.797 mill
|
| EPS: |
0.0100
|
| P/E: |
0.250
|
| Earnings Date: |
N/A |
| SharesOutstanding: |
318.75 mill
|
| Avg Daily Volume: |
1.262 mill
|
| RATING
2024-05-03 |
|
C+
|
|
Sell
|
| RATINGS |
| Rating CashFlow: |
Sell
|
|
| Return On Equity: |
Strong Buy
|
|
| Return On Asset: |
Strong Sell
|
|
| DE: |
Strong Sell
|
|
| P/E: |
Sell
|
|
| Price To Book: |
Strong Sell
|
|
| QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
| Revenue | | | | | | |
| Gr.Profit | | | | | | |
| Ebit | | | | | | |
| Asset | | | | | | |
| Debt | | | | | | |
| PE RATIO: COMPANY / SECTOR |
|
0.00x
|
|
Company: PE 0.250 | sector: PE -11.58
|
| PE RATIO: COMPANY / INDUSTRY |
|
0x
|
|
Company: PE 0.250 | industry: PE -107.25
|
| DISCOUNTED CASH FLOW VALUE |
|
N/A
|
|
N/A
|
| Expected Trading Range (DAY) |
$ 0.0015 - 0.0035
( +/- 40.00%)
|
|
ATR Model: 14 days
|
Insider Trading
| Date |
Person |
Action |
Amount |
type |
| 2020-07-01 | Collier Alan Brian | Buy | 100 | Common Stock |
| 2020-07-01 | Collier Alan Brian | Buy | 100 | Common Stock |
| 2020-06-30 | Collier Alan Brian | Buy | 200 | Common Stock |
| 2020-02-22 | Collier Alan Brian | Buy | 100 | Common Stock |
| 2020-01-02 | Collier Alan Brian | Buy | 100 | Common Stock |
| INSIDER POWER |
|
0.00
|
| Last
100 transactions |
| Buy:
301 200 | Sell:
0 |
Forecast:
14:10 - $0.0020
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
| Indicator Signals |
| RSI 21 |
|
| SMA |
|
| Trend |
|
| Trend 2 |
|
| Trend 3 |
|
| Volume Signals |
| Price |
$0.0025 (25.94% )
|
| Volume |
0.0203 mill
|
| Avg. Vol. |
1.262 mill
|
| % of Avg. Vol |
1.609 %
|
| Signal 1: |
|
| Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ENDV
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
The Technical Analyst
